Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 5/20 | 0.50 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24765225 | 1.00 | CTSB (0.54) | CTSBOPRM1OPRD1OPRK1ACE | |
| SCHEMBL24765340 | 0.95 | ACE (0.51) | CTSBACEMMECPA1ACE2 | |
| SCHEMBL24765356 | 0.95 | ACE (0.51) | CTSBACEMMECPA1ACE2 | |
| SCHEMBL25335274 | 0.90 | ACE (0.56) | ACEMMECPA1ACE2 | |
| SCHEMBL25760226 | 0.87 | CTSS (0.49) | CTSBOPRM1OPRD1OPRK1CTSL | |
| SCHEMBL24765226 | 0.84 | CTSB (0.57) | CTSBOPRM1OPRD1OPRK1ACE | |
| SCHEMBL24765349 | 0.84 | CTSS (0.53) | CTSBOPRM1OPRD1OPRK1ACE | |
| SCHEMBL24765350 | 0.84 | CTSS (0.53) | CTSBOPRM1OPRD1OPRK1ACE | |
| SCHEMBL23142823 | 0.83 | CTSB (0.55) | CTSBOPRM1OPRD1OPRK1ACE | |
| SCHEMBL23142822 | 0.83 | CTSB (0.55) | CTSBOPRM1OPRD1OPRK1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | CTSB 104/4885OPRM1 2130/4885OPRD1 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.